Blue Zone Wealth Advisors LLC Buys 1,044 Shares of Danaher Co. (NYSE:DHR)

Blue Zone Wealth Advisors LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 7.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 15,893 shares of the conglomerate’s stock after purchasing an additional 1,044 shares during the quarter. Blue Zone Wealth Advisors LLC’s holdings in Danaher were worth $4,419,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after buying an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the period. Legal & General Group Plc increased its stake in Danaher by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after buying an additional 139,989 shares in the last quarter. Finally, Capital Research Global Investors grew its position in shares of Danaher by 1.0% during the first quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock worth $1,279,932,000 after purchasing an additional 52,679 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.5 %

Shares of NYSE:DHR opened at $268.79 on Tuesday. The company has a market capitalization of $199.09 billion, a PE ratio of 45.56, a P/E/G ratio of 4.55 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The business’s fifty day simple moving average is $271.07 and its 200-day simple moving average is $258.64.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 earnings per share. As a group, equities research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Robert W. Baird raised their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. The Goldman Sachs Group boosted their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Stifel Nicolaus upped their target price on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Stephens assumed coverage on Danaher in a research report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 target price for the company. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.